Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
29.5.2024 17:00:00 EEST | Business Wire | Press release
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
LACRIFILL Canalicular Gel allows patient’s eyes to be bathed in their own natural tears. It is customized for each individual patient and provides a full fill of the canalicular system. LACRIFILL Canalicular Gel is administered through a simple in-office procedure, which is reimbursed through the existing CPT code (68761), and the results last for six months.
“It’s been so exciting to be part of the launch of LACRIFILL Canalicular Gel, an interventional dry eye treatment that helps ophthalmologists with cataract, glaucoma and refractive surgeries and all of their dry eye needs. This dry eye therapy is truly changing practice and changing lives,” said Chief Commercial Officer of Eye Care U.S., Jai Parekh, MD, MBA.
Nordic Pharma is attending Kiawah Eye 2024 in Kiawah Island, SC from May 30-June 1 to share information about LACRIFILL Canalicular Gel and take orders. "LACRIFILL Canalicular Gel is a disruptive technology that will change how ophthalmologists practice,” said Program Director for Kiawah Eye and chairperson of the LACRIFILL U.S. Medical Advisory Board, Eric D. Donnenfeld, MD. “Having Nordic Pharma onsite to discuss how LACRIFILL Canalicular Gel will optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms will be incredibly beneficial for Kiawah Eye attendees.”
For more information about LACRIFILL Canalicular Gel and ordering details visit lacrifill.com.
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Group has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.
Nordic Group is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
About Nordic Pharma, Inc.
Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma’s business developments and the implementation of Nordic Group /Nordic Pharma’s strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma’s business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529287049/en/
Contact information
Nordic Pharma, Inc.
Kate Popova
Contracts Administration Lead
Phone Number: 610-285-1699
ekaterina.popova@nordicpharma.com
Gail Feerrar
Director Sales and Marketing
Phone: 610-285-7152
gail.feerrar@nordicpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Can Design the Slides, But It Can’t Fix Stage Fright: 3 in 4 Workers Get Anxious Presenting, Canva Study Finds8.9.2026 16:00:00 EEST | Press release
New research from Canva, the world’s leading visual communication platform, reveals an emerging paradox at the heart of one of work’s age-old skills: even as AI makes presentations easier to create than ever, nearly three in four professionals (74%) still feel anxious about presenting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908549712/en/ Canva's Global 'The Presentation Paradox' Study Few things are as entrenched as presentations, and decade after decade, they’ve defined how we communicate to clients, teammates, leadership, and beyond. Now, AI is changing them by making them faster and easier to create than ever. Nine in 10 (91%) workers use AI monthly to build slides, mainly for design (57%), brainstorming (56%) and drafting content (49%). 48% say it saves them more than an hour per presentation. As AI use grows, more than 100 million people create presentations on Canva every month, and it is one of the top use
PAX Debuts The Oxblood Edit, a Limited Edition Collection Inspired by Fall’s Richest Color8.9.2026 16:00:00 EEST | Press release
Today PAX, a pioneering global cannabis brand, introduces The Oxblood Edit, an ultra-limited release bringing one of fall’s defining colors to three of the brand’s signature devices: PAX FOUR, PAX MINI and ERA GO. Deep, distinctive and designed to be coveted, Oxblood transforms the PAX lineup through a rich burgundy finish inspired by the worlds of fashion, interiors and industrial design. The limited collection is available beginning today at pax.com and select retailers, while supplies last. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908330141/en/ The Oxblood Edit: bringing timeless style, seasonal color, and elevated design to three of the brand's signature devices. Long associated with craftsmanship and enduring style, oxblood has reemerged across fashion, footwear, accessories and interiors as consumers gravitate toward richer palettes, timeless materials and elevated essentials. For PAX, the color is less about
STARTEEPO Issues Letter and Presentation to the Board of Xerox Calling for Action to Unlock Shareholder Value8.9.2026 16:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”) today issued an investor presentation and the following letter to the Board of Directors (the “Board”) of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX). STARTEEPO, which has increased its investment in Xerox to a beneficial ownership of 7.34%, in stocks and options, is urging the Board to take bold actions to unlock significant shareholder value, including by increasing transparency about Xerox Financial Services’ performance, evaluating strategic alternatives for the business unit, deleveraging the Company, and exercising continued capital discipline. Shareholders can view the investor presentation here. For more information visit: www.starteepo.com/xerox. The full text of the letter follows: September 7, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Since we first wrote to you in May, we have increased our already significant investment in Xerox Holdings Corp. to a b
Leblon Delienne Joins LEXON at BOW to Expand Its Global Reach8.9.2026 15:36:00 EEST | Press release
BOW (Brands of Wonder), the international brand group behind French design brand LEXON, today announced the acquisition of Leblon Delienne, the French sculpture atelier known for transforming pop culture icons into collectible art and design objects. The move pairs the atelier’s distinctive French craftsmanship and licensed collections with BOW’s international reach and digital expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908641342/en/ Leblon Delienne Joins LEXON at BOW Juliette de Blegiers, who acquired the company in 2018, will remain a minority shareholder in Leblon Delienne and continue working alongside BOW founder Boris Brault and the atelier’s teams. For more than 40 years, Leblon Delienne has brought iconic characters to life through sculptures, figurines, furniture, and art and design objects, primarily in limited, numbered editions. Its licensed collections feature characters from Disney, Warner Bro
Visa Brings Onchain Lending into Everyday Payments8.9.2026 15:00:00 EEST | Press release
Today, Visa (NYSE: V) announced a new approach to onchain credit designed to help stablecoin-linked card programs and fintechs access working capital using onchain lending infrastructure and Visa data. Onchain lending has emerged as one of the fastest-growing segments of digital finance. According to the Visa Onchain Analytics Dashboard, since 2020, more than $694 billion in stablecoin-denominated loans have been sent through onchain lending protocols, creating a global credit market that operates 24/7. Yet much of that activity remains concentrated within crypto markets and hasn’t meaningfully supported the businesses and payment experiences people use every day. Visa is helping bridge that gap by combining VisaNet settlement data with onchain credit infrastructure. This information can help lenders better understand how a program is operating, making it easier to evaluate financing opportunities that fit their needs and extend capital to support their goals. "Stablecoins are not only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom